chr3-37028730-C-T
Variant names: 
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000249.4(MLH1):c.1410-54C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0131 in 1,612,036 control chromosomes in the GnomAD database, including 935 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).
Frequency
 Genomes: 𝑓 0.045   (  460   hom.,  cov: 32) 
 Exomes 𝑓:  0.0097   (  475   hom.  ) 
Consequence
 MLH1
NM_000249.4 intron
NM_000249.4 intron
Scores
 2
Clinical Significance
Conservation
 PhyloP100:  -0.00800  
Publications
4 publications found 
Genes affected
 MLH1  (HGNC:7127):  (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017] 
MLH1 Gene-Disease associations (from GenCC):
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
- Lynch syndrome 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Genomics England PanelApp, Ambry Genetics, G2P, Orphanet
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae), Orphanet, ClinGen
- Lynch syndrome 1Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.62). 
BP6
Variant 3-37028730-C-T is Benign according to our data. Variant chr3-37028730-C-T is described in ClinVar as Benign. ClinVar VariationId is 89722.Status of the report is reviewed_by_expert_panel, 3 stars. 
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.142  is higher than 0.05. 
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  0.0455  AC: 6912AN: 152040Hom.:  458  Cov.: 32 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
6912
AN: 
152040
Hom.: 
Cov.: 
32
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD4 exome  AF:  0.00975  AC: 14230AN: 1459878Hom.:  475   AF XY:  0.00960  AC XY: 6975AN XY: 726416 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
14230
AN: 
1459878
Hom.: 
 AF XY: 
AC XY: 
6975
AN XY: 
726416
show subpopulations 
African (AFR) 
 AF: 
AC: 
5030
AN: 
33436
American (AMR) 
 AF: 
AC: 
488
AN: 
44716
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
71
AN: 
26130
East Asian (EAS) 
 AF: 
AC: 
3
AN: 
39670
South Asian (SAS) 
 AF: 
AC: 
1601
AN: 
86200
European-Finnish (FIN) 
 AF: 
AC: 
59
AN: 
53348
Middle Eastern (MID) 
 AF: 
AC: 
243
AN: 
5756
European-Non Finnish (NFE) 
 AF: 
AC: 
5817
AN: 
1110302
Other (OTH) 
 AF: 
AC: 
918
AN: 
60320
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.499 
Heterozygous variant carriers
 0 
 749 
 1499 
 2248 
 2998 
 3747 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
 0 
 304 
 608 
 912 
 1216 
 1520 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome  0.0455  AC: 6920AN: 152158Hom.:  460  Cov.: 32 AF XY:  0.0449  AC XY: 3344AN XY: 74404 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
6920
AN: 
152158
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
3344
AN XY: 
74404
show subpopulations 
African (AFR) 
 AF: 
AC: 
6037
AN: 
41486
American (AMR) 
 AF: 
AC: 
324
AN: 
15288
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
9
AN: 
3466
East Asian (EAS) 
 AF: 
AC: 
2
AN: 
5180
South Asian (SAS) 
 AF: 
AC: 
76
AN: 
4820
European-Finnish (FIN) 
 AF: 
AC: 
18
AN: 
10600
Middle Eastern (MID) 
 AF: 
AC: 
12
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
363
AN: 
68000
Other (OTH) 
 AF: 
AC: 
79
AN: 
2112
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.503 
Heterozygous variant carriers
 0 
 309 
 618 
 928 
 1237 
 1546 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
 0 
 74 
 148 
 222 
 296 
 370 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
40
AN: 
3478
ClinVar
Significance: Benign 
Submissions summary: Benign:8 
Revision: reviewed by expert panel
LINK: link 
Submissions by phenotype
not provided    Benign:3 
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Jun 19, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
not specified    Benign:1 
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Colorectal cancer, hereditary nonpolyposis, type 2    Benign:1 
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Lynch syndrome    Benign:1 
Sep 05, 2013
International Society for Gastrointestinal Hereditary Tumours (InSiGHT)
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:research
MAF >1% -
Muir-Torré syndrome    Benign:1 
Feb 01, 2025
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Hereditary cancer-predisposing syndrome    Benign:1 
Dec 20, 2018
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.